Saad Mark E 4
4 · Axsome Therapeutics, Inc. · Filed Sep 5, 2025
Insider Transaction Report
Form 4
Saad Mark E
Director
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2025-09-05−9,127→ 0 totalExercise: $9.00From: 2016-11-19Exp: 2025-11-19→ Common Stock (9,127 underlying) - Exercise/Conversion
Common Stock
2025-09-05$9.00/sh+9,127$82,143→ 19,129 total - Sale
Common Stock
2025-09-05$125.07/sh−9,127$1,141,514→ 10,002 total
Holdings
- 300(indirect: See explanation 5 below.)
Common Stock
Footnotes (5)
- [F1]Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur within the next two months.
- [F2]Such transaction was pursuant to a pre-approved 10b5-1 plan which has now been completed.
- [F3]Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
- [F4]Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $125.00 and $125.22.
- [F5]Represents additional shares held indirectly by the Reporting Person prior to September 5, 2025 which includes shares indirectly beneficially owned by Mr. Saad as custodian for his children's UTMA accounts.